Evidence map›Paper›PMID 35098034›Full record

ArticleSN comprehensive clinical medicine2021

Botanical Interventions to Improve Glucose Control and Options for Diabetes Therapy.

Peter Smoak, Susan J Burke, J Jason Collier

Abstract read
In one paragraph

Article in SN comprehensive clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Efficacy and safety ofFrontiers in pharmacology · 2025
    Trial
  3. Review
  4. Effect of Resveratrol on the intestinal microbiota in Type2 diabetes Mellitus mice.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  5. UPLC-ESI-QTOF-MS Profiling of Phenolic Compounds fromMolecules (Basel, Switzerland) · 2022
    Article
  6. Article
  7. Biomolecules · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Peter SmoakLaboratory of Islet Biology and Inflammation, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA.
Susan J BurkeImmunogenetics Laboratory, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, LA 70808 Baton Rouge, USA.
J Jason CollierLaboratory of Islet Biology and Inflammation, Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA.

Funding

The role of maternal obesity-driven inflammation and adverse pregnancy outcomes in a mouse model of preeclampsiaP20GM135002 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Jacqueline M Stephens · 2020 to 2026
$18.4M
Training in Botanical Approaches to Combat Metabolic SyndromeT32AT004094 · NCCIH · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI BRANTLEY, PHILLIP J, STEPHENS, JACQUELINE M · 2009 to 2024
$5.7M
Astrocytes, Glucose Detection, and Counter-RegulationR01DK108765 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI ROGERS, RICHARD C. · 2016 to 2020
$2.1M
SGK1 is a regulator of islet beta cell mass and secretory functionR01DK123183 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI COLLIER, JAMES JASON · 2020 to 2024
$1.8M
Glial-Neural Interactions in Autonomic ControlR01NS060664 · NINDS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI ROGERS, RICHARD C. · 2008 to 2012
$1.6M
A Unique Receptor Agonist Approach for Type 1 Diabetes PreventionR21AI138136 · NIAID · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI COLLIER, JAMES JASON · 2018 to 2019
$436k
Development of Mice with Conditional ICAM-1 DeletionR03AI151920 · NIAID · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI COLLIER, JAMES JASON · 2020 to 2021
$153k
NCCIH NIH HHS T32 AT004094NIAID NIH HHS R03 AI151920NIAID NIH HHS R21 AI138136NIDDK NIH HHS R01 DK108765NIDDK NIH HHS R01 DK123183NIGMS NIH HHS P20 GM135002NINDS NIH HHS R01 NS060664
6 · The paper itself

Abstract

Diabetes mellitus is a major public health problem worldwide. This endocrine disease is clustered into distinct subtypes based on the route of development, with the most common forms associated with either autoimmunity (T1DM) or obesity (T2DM). A shared hallmark of both major forms of diabetes is a reduction in function (insulin secretion) or mass (cell number) of the pancreatic islet beta-cell. Diminutions in both mass and function are often present. A wide assortment of plants have been used historically to reduce the pathological features associated with diabetes. In this review, we provide an organized viewpoint focused around the phytochemicals and herbal extracts investigated using various preclinical and clinical study designs. In some cases, crude extracts were examined directly, and in others, purified compounds were explored for their possible therapeutic efficacy. A subset of these studies compared the botanical product with standard of care prescribed drugs. Finally, we note that botanical formulations are likely suspects for future drug discovery and refinement into class(es) of compounds that have either direct or adjuvant therapeutic benefit.

Indexed as

BotanicalDiabetesInflammationIsletObesity

Identifiers

PMID35098034
PMCPMC8796700

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.